Company Profile
We are a drug discovery bio-venture originated from Asahikawa Medical University, established based on the research of Professor Mikihiro Fujiya’s group, Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology/Oncology, Department of Medicine, Asahikawa Medical University.
We were founded in April 2018 after inheriting research from Asahikawa Medical University and Sapporo Holdings Co., Ltd. on the "development of novel therapeutic agents for inflammatory bowel disease using probiotic-derived long-chain polyphosphoric acid".
We are conducting research and development of candidate substances for new therapeutic agents utilizing probiotic-derived bioactive substances in the gastrointestinal and anticancer fields.
Company name
Kamui Pharma, Inc.
Company establishment date
4/2, 2018
Business content
Pharmaceuticalization of bioactive substances derived from probiotics (effective microorganisms)
Board member
CEO
Naoki OGAWA（Associate Professor of Intellectual Property Center, Asahikawa Medical University）
CSO
Mikihiro FUJIYA（Proffessor of Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology/Oncology, Department of Medicine,
Asahikawa Medical University）
Director
Hiroyuki HASEGAWA（Operating Officer of Mitsubishi UFJ Capital Co., Ltd.）
Accounting adviser
Kenji MAEKAWA（Representative of MAEKAWA CPA Office）